ArticleAsia-Pacific journal of clinical oncology2026
Cost of Treating Patients Who Undergo Resection of Colorectal Liver Metastases: An Australian Pilot Study.
Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe cost of treating cancer, especially metastatic disease, can place a financial burden on patients, caregivers, and the healthcare system. A previous systematic review assessing the cost of treating metastatic colorectal cancer in the era of personalized medicine showed that this was approximately 300,000 USD. Surprisingly, there is little data on the cost of treating patients with colorectal liver metastases (CRLM). The aim of this study was to conduct a pilot cost-of-illness study on patients who undergo liver resection for CRLM in Australia.
methodsThis was a retrospective cohort study examining the direct medical costs to the healthcare system and out-of-pocket costs to patients who underwent resection for CRLM in 1 year (2018). These costs were calculated in 2022 Australian dollars from the time of the diagnosis of the liver metastases to the time of the last follow-up.
resultsA total of 25 patients underwent resection in 2018, but only 16 received all their treatment at the Northern Campus. The median total cost of treating each patient was $328,773.59 (range: $63,244.40-$525,873.10). The highest cost was for medical oncology treatment, with a median of $90,228.87 per patient (range: $2087.06-$241,514.80), followed by liver surgery and consultations, $57,131.76 (range: $12,455.10-$319,178.90), and colorectal surgery and consultations, $55,990.29 (range: $7234.19-$200,755.60). Patients considered to be cured of their disease had a lower median cost than patients who had either died from their disease or were undergoing treatment for recurrent disease ($152,476.50 vs. $351,487.50, p = 0.030).
conclusionThis study demonstrates that the cost of treating patients with CRLM in Australia is moderate but is considerably lower than many other cancer types, especially for those who are cured, reflecting good value care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.